Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:01:54 EDT Wed 01 May 2024
Enter Symbol
or Name
USA
CA



Q:QLGN - QUALIGEN THERAPEUTICS INC - https://www.qualigeninc.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
QLGN - Q0.10.291·0.33430.10.2997-0.0003-0.139.810700.301  0.3124  0.29141.26  0.283116:41:47Apr 1615 min RT 2¢

Recent Trades - Last 10 of 70
Time ETExPriceChangeVolume
16:41:47Q0.3080.00821
16:02:12Q0.30410.004315
16:02:08Q0.2998 80
16:00:00Q0.2998 27
16:00:00Q0.2998 6
15:57:43Q0.2911-0.008711
15:51:52Q0.2997-0.00031,400
15:44:54Q0.2914-0.0086100
15:41:11Q0.2959-0.00391
15:26:02Q0.2914-0.008449

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-16 07:00U:QLGNNews ReleaseMarizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft(TM)
2024-04-10 08:00U:QLGNNews ReleaseQualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
2024-04-09 08:00U:QLGNNews ReleaseQualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
2023-11-14 16:30U:QLGNNews ReleaseQualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
2023-11-07 08:30U:QLGNNews ReleaseQualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
2023-10-23 08:30U:QLGNNews ReleasePoster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer
2023-09-27 08:30U:QLGNNews ReleaseQualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023
2023-08-17 08:30U:QLGNNews ReleaseQualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors
2023-08-15 08:30U:QLGNNews ReleaseQualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023
2023-08-01 08:30U:QLGNNews ReleaseQualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
2023-07-24 08:15U:QLGNNews ReleaseQualigen Therapeutics Divests FastPack ‚ ® Diagnostics Business
2023-06-05 08:15U:QLGNNews ReleasePoster Highlighting Qualigen Therapeutics ¢ € ™ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
2023-05-16 08:00U:QLGNNews ReleaseQualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023